India, Aug. 19 -- Chemomab Therapeutics Ltd. (CMMB), a clinical-stage biotech company, on Wednesday released financial results for the second quarter ended June 30, 2026.
Company Profile
Israel-based Chemomab is focused on developing therapies for fibro-inflammatory diseases with high unmet medical needs. The company's lead candidate, Nebokitug, is a monoclonal antibody designed to target and neutralize CCL24, a protein involved in fibrosis and inflammation.
The drug is being evaluated for primary sclerosing cholangitis. The candidate has received U.S. FDA and EMA Orphan Drug Designation and Fast Track Status for the indication.
Q2 FY26 Highlights
For the second quarter, net loss was $2.16 million, marginally wider compared to $2.06 mi...